Source: Lieyunwang
Hangzhou Nansu Technology, a company that has been deeply engaged in digital therapeutics for neurological rehabilitation for many years, is upgrading its corporate positioning from a provider of pediatric rehabilitation digital therapeutics to a full-lifecycle neurological rehabilitation technology platform, and has completed a Pre-B financing round worth tens of millions of yuan.
This round of financing was led by Plum Ventures, with Jiangxi Financial Holdings Group participating as a co-investor. The funds raised will be primarily allocated to the research and development of the "Time Target" closed-loop brain-computer interface technology platform; the clinical validation, regulatory submission, and commercialization of combined therapy products integrating digital therapeutics and electrical neuromodulation; and the further enhancement of the industrial ecosystem and service network.
In terms of data, Nans Tech’s “Xiao Nan Ting Shuo” series products have covered more than 1,300 hospitals and rehabilitation centers across China, cumulatively serving over 50,000 children with neurodevelopmental disorders and accumulating millions of hours of training and efficacy data. These real-world data constitute a crucial foundation for the company’s expansion into closed-loop brain-computer interfaces.
From a technical perspective, it is understood that the founding team of Nans Tech possesses years of experience in the industrialization of neuroelectrical stimulation products, such as cochlear implants, and has accumulated extensive innovation and practical expertise in core technologies like dynamic neural coding strategies. This foundation enables the company to operate not merely as a cross-industry entrant from the niche field of digital therapeutics, but rather with established roots in both digital rehabilitation and neuroelectrical stimulation.